Compare McCormick & Company, Incorporated (MKC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs BIO-TECHNE Corp — how do they compare? McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: McCormick & Company, Incorporated and BIO-TECHNE Corp are close in size by market cap, and McCormick & Company, Incorporated pays the higher dividend (4.18%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and BIO-TECHNE Corp for 64 Days on average.
| MKC | TECH | |
|---|---|---|
Market Cap | $12.39B | $11.36B |
Volume | 6,140,872 | 5,390,331 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $72.61 |
52-Week Low | $44.14 | $43.31 |
Typical Hold Time | 67 Days | 64 Days |
Enterprise Value | $17.07B | $11.39B |
Dividend Yield | 4.18% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.94, up 1.52% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q3 2026 results with 17% sales growth and margin expansion, though net cash flow was negative $90.2M in 2025. Valuation metrics appear attractive with P/E of 8.31 and ROE of 23.37%, while analyst consensus is mixed with 33% buy ratings.
The stock offers value potential with a $53.50 price target upside, supported by dividend payments and operational strength. Key risks include integration challenges from recent acquisitions and macroeconomic pressure on consumer spending. The technical picture suggests near-term resistance at $46-$47 levels despite fundamental strength.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
